ASU Biodesign Institute executive director urges health care forces to ‘go beyond discovery’ at Arizona Wellbeing Commons conference

With organizations the caliber of Mayo Clinic, TGen, the Flinn Foundation, Arizona BioIndustry Association and the state’s universities, Arizona boasts a multitude of talented scientists, health professionals, life science entrepreneurs, nonprofits and government leaders committed to contributing to the quality of life in our state. Arizona’s bioscience sector is adding jobs at a rate that outpaces the nation. And its public universities are seeing increases in bioscience research funding, expenditures and tech transfer.Continue reading

Kalos Therapeutics, Inc., Oncology Pharmaceuticals and NanoSmart Pharmaceuticals Inc., combination therapy offers the potential of a safer and more effective approach to a wide variety of cancer treatments

Oncology Pharma is pleased to announce that Kalos Therapeutics’ lead compound, KTH-222, can produce a reduction in the attachment of newly seeded cells to a solid-phase by an average of 39%. These non-clinical results suggest that KTH-222 disrupt tubulin formation and attachment to the solid-phase in a similar way to most of the commonly used tubulin disrupting chemotherapeutic drugs. However, the mechanism of action by KTH-222 may be different than the most commonly used tubulin-disrupting therapies and needs further investigation. Continue reading